Actively Recruiting
Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Led by Isfahan University of Medical Sciences · Updated on 2025-09-15
20
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA). OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS). MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA. Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity. This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.
CONDITIONS
Official Title
Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chronic history (for at least 3 months) of knee joint pain
- Body mass index (BMI) between 21.5 and 29.5
- Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence radiographic classification scale)
You will not qualify if you...
- Rheumatoid arthritis and other rheumatic diseases
- Varus or valgus deformity more than 10 degrees; lateral subluxation of the patella
- Deformity at or near the knee joint due to fracture or other injury
- Complete rupture of ligament or meniscus causing laxity or locking
- Serious systemic, blood, autoimmune diseases; history of severe allergy; serious organ failure; inability to walk
- Hyaluronic acid injection in the past six months
- Hemoglobin levels below 10 g/dL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Leila Dehghani
Isfahan, Iran
Actively Recruiting
Research Team
L
Leila Dehghani, Dr
CONTACT
M
Masoud Soleimani, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here